| NDC Number | Brand Name | Generic Name | Manufacturer | Dosage Form | DEA Sch. | Marketing Start Date |
|---|---|---|---|---|---|---|
| 0069-0238 | Ruxience | rituximab-pvvr | Pfizer Laboratories Div Pfizer Inc | INJECTION, SOLUTION | 2020-01-23 | |
| 0069-0249 | Ruxience | rituximab-pvvr | Pfizer Laboratories Div Pfizer Inc | INJECTION, SOLUTION | 2020-01-23 | |
| 0078-0669 | ARZERRA | ofatumumab | Novartis Pharmaceuticals Corporation | INJECTION, SOLUTION | 2016-02-01 | |
| 0078-0690 | ARZERRA | ofatumumab | Novartis Pharmaceuticals Corporation | INJECTION, SOLUTION | 2016-02-01 | |
| 0078-1007 | KESIMPTA | ofatumumab | Novartis Pharmaceuticals Corporation | INJECTION, SOLUTION | 2009-10-26 | |
| 50242-051 | Rituxan | rituximab | Genentech, Inc. | INJECTION, SOLUTION | 1997-11-26 | |
| 50242-053 | Rituxan | rituximab | Genentech, Inc. | INJECTION, SOLUTION | 1997-11-26 | |
| 50242-070 | Gazyva | obinutuzumab | Genentech, Inc. | INJECTION, SOLUTION, CONCENTRATE | 2013-11-01 | |
| 50242-108 | Rituxan Hycela | rituximab and hyaluronidase | Genentech, Inc. | INJECTION, SOLUTION | 2017-06-22 | |
| 50242-109 | Rituxan Hycela | rituximab and hyaluronidase | Genentech, Inc. | INJECTION, SOLUTION | 2017-06-22 | |
| 50242-150 | OCREVUS | ocrelizumab | Genentech, Inc. | INJECTION | 2017-03-28 | |
| 50242-554 | Ocrevus Zunovo | ocrelizumab and hyaluronidase | Genentech, Inc. | INJECTION, SOLUTION | 2024-09-13 | |
| 55513-224 | Riabni | rituximab-arrx | Amgen, Inc | INJECTION, SOLUTION | 2021-01-06 | |
| 55513-326 | Riabni | rituximab-arrx | Amgen, Inc | INJECTION, SOLUTION | 2021-01-06 | |
| 63459-103 | Truxima | rituximab-abbs | Cephalon, Inc. | INJECTION, SOLUTION | 2020-05-04 | |
| 63459-104 | Truxima | rituximab-abbs | Cephalon, Inc. | INJECTION, SOLUTION | 2020-05-04 | |
| 73150-150 | BRIUMVI | ublituximab | TG Therapeutics, Inc. | INJECTION, SOLUTION, CONCENTRATE | 2022-12-28 |
Loading full table content...